https://charts.traderzeitung.de/phases/US6979471090 string(1406) "{"isin":"US6979471090","name":"Palvella Therapeutics Inc","stock_id_xnas":67820195,"stock_id_xnys":null,"generated_at":"2026-08-09 08:04:00","days":[{"date":"2026-08-05","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":155.538,"close_at":"2026-08-05 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-06","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":154.73,"close_at":"2026-08-06 21:59:00","complete":true,"perf_pct":-0.5195},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-07","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":157.6,"close_at":"2026-08-07 21:59:00","complete":true,"perf_pct":1.8548},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"

Palvella Therapeutics Aktie News & Nachrichten

[WKN: A40RA6 | Symbol: PVLA]

Realtimekurs

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

10J

Alles

Artikel aus der Redaktion der Trader-Zeitung

02.03.2026 um 13 Uhr

Palvella Therapeutics

TOP-5-Kursziele der Analysten am 02.03.26

Palvella Therapeutics [US6979471090] Clear Street besätigt Buy-Rating und erhöht das Kursziel von...

05.12.2025 um 13 Uhr

TOP-5-Kursziele der Analysten am 05.12.25

Rubrik [US7811541090] Baird bekräftigt Buy-Rating und erhöht das Kursziel von 120 auf 130 USD (56...

19.11.2025 um 13 Uhr

TOP-5-Kursziele der Analysten am 19.11.25

Ottobock [DE000BCK2223] Goldman Sachs startet Berichterstattung mit "Buy" und Kursziel 100 Euro (37...

Palvella Therapeutics Nachrichtenticker öffnen

MT Newswires 04.08.2026 15:37 Uhr

Palvella Therapeutics verzeichnet größeren Nettoverlust im Q2

09:36 AM EDT, 04.08.2026 (MT Newswires) -- Palvella Therapeutics (PVLA) meldete am Dienstag für das Q2 einen Nettoverlust von 1,52 $ je verwässerter A

MT Newswires 04.08.2026 13:40 Uhr

--Earnings Flash (PVLA) Palvella Therapeutics verzeichnet Q2 Nettoverlust von 1,52 USD je Aktie, verglichen mit FactSet-Schätzung von 1,07 USD Verlust

MT Newswires 22.06.2026 14:27 Uhr